Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is a non‑ionic iodinated contrast media presented as a sterile aqueous solution for intravenous and intra‑arterial use. It enhances radiographic visibility during diagnostic imaging procedures in patients undergoing angiography, computed tomography, urography and related studies.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions globally effectively.

Optiray (ioversol) is employed in radiographic procedures to improve image contrast across various vascular and organ systems.

- Angiography: enhances visualization of blood vessels, allowing detailed assessment of arterial and venous anatomy. - Computed Tomography (CT) scans: increases tissue differentiation, facilitating detection of lesions and structural abnormalities. - Urography: delineates the urinary tract, improving identification of stones, tumors, and obstruction. - Cardiac catheterization: provides clear contrast of coronary arteries for functional and anatomical evaluation. - Venography: highlights venous structures to aid in diagnosis of thrombosis and vascular disorders.

Adverse reactions to Optiray may range from mild, transient sensations to rare but serious systemic events.

Common Side Effects: - Warm sensation: brief feeling of heat during injection. - Metallic taste: transient metallic flavor in the mouth. - Nausea: mild stomach upset shortly after administration. - Flushing: temporary skin reddening and warmth.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response that can be life‑threatening. - Contrast‑induced nephropathy: acute kidney injury, particularly in patients with pre‑existing renal dysfunction. - Cardiovascular collapse: sudden drop in blood pressure and heart function.

Prior to using Optiray, clinicians should evaluate patient risk factors and follow specific handling guidelines to minimize adverse outcomes. - Assess renal function: obtain baseline serum creatinine and eGFR to identify at‑risk patients. - Screen for iodine allergy: review patient history for prior reactions to contrast media. - Ensure adequate hydration: encourage fluid intake before and after the procedure to support renal clearance. - Use lowest effective dose: tailor the volume of ioversol to the imaging requirement. - Avoid in severe hyperthyroidism: high iodine load may exacerbate thyroid hormone excess. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Optiray may interact with other agents, influencing safety or efficacy; awareness of these interactions helps guide clinical decisions.

Major Interactions (Avoid): - Concurrent iodinated contrast agents: cumulative iodine exposure increases risk of nephrotoxicity and allergic reactions. - Nephrotoxic drugs (e.g., aminoglycosides, high‑dose NSAIDs): combined use heightens potential for renal impairment.

Moderate Interactions (Monitor Closely): - Metformin: consider temporary discontinuation in patients with reduced renal function to prevent lactic acidosis. - Beta‑blockers: may mask tachycardia during anaphylactoid reactions, requiring close monitoring. - Thyroid hormone therapy: monitor thyroid function tests as iodine load can affect hormone levels.